Li Yanan, Mao Ling, Gao Yuan, Baral Suraj, Zhou Yifan, Hu Bo
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Sci Rep. 2015 Aug 21;5:13316. doi: 10.1038/srep13316.
Previous studies have suggested that microRNA-107 (miR-107) regulates cell migration in tumor and promotes Hypoxia Inducible Factor 1α (HIF1α) regulated angiogenesis under hypoxia. We found that miR-107 was strongly expressed in ischemic boundary zone (IBZ) after permanent middle cerebral artery occlusion (pMCAO) in rats and inhibition of miR-107 could reduce capillary density in the IBZ after stroke. Such finding led us to hypothesize that miR-107 might regulate post-stroke angiogenesis and therefore serve as a therapeutic target. We also found that antagomir-107, a synthetic miR-107 inhibitor, decreased the number of capillaries in IBZ and increased overall infarct volume after pMCAO in rats. We demonstrated that miR-107 could directly down-regulate Dicer-1, a gene that encodes an enzyme essential for processing microRNA (miRNA) precursors. This resulted in translational desupression of VEGF (vascular endothelial growth factor) mRNA, thereby increasing expression of endothelial cell-derived VEGF (VEGF165/VEGF164), leading to angiogenesis after stroke. This process might be a protective mechanism for ischemia-induced cerebral injury and miR-107 might be used as a novel tool in stroke treatment.
先前的研究表明,微小RNA-107(miR-107)在肿瘤中调节细胞迁移,并在缺氧条件下促进缺氧诱导因子1α(HIF1α)调节的血管生成。我们发现,在大鼠永久性大脑中动脉闭塞(pMCAO)后,miR-107在缺血边界区(IBZ)中强烈表达,抑制miR-107可降低中风后IBZ中的毛细血管密度。这一发现使我们推测,miR-107可能调节中风后的血管生成,因此可作为治疗靶点。我们还发现,抗miR-107(一种合成的miR-107抑制剂)可减少大鼠pMCAO后IBZ中的毛细血管数量,并增加总体梗死体积。我们证明,miR-107可直接下调Dicer-1,该基因编码一种处理微小RNA(miRNA)前体所必需的酶。这导致血管内皮生长因子(VEGF)mRNA的翻译抑制,从而增加内皮细胞衍生的VEGF(VEGF165/VEGF164)的表达,导致中风后血管生成。这一过程可能是缺血性脑损伤的一种保护机制,miR-107可能用作中风治疗的新工具。
CNS Neurosci Ther. 2016-2-28
Aging (Albany NY). 2019-5-7
Mol Cell Biochem. 2012-7-26
Int J Mol Sci. 2025-4-22
Cell Mol Life Sci. 2025-2-22
J Inflamm Res. 2024-7-12
Curr Med Chem. 2024
Acta Pharmacol Sin. 2023-7
Front Mol Neurosci. 2023-2-2
J Clin Invest. 2013-2-15
Oncogene. 2013-2-18
J Biol Chem. 2012-6-28
J Huazhong Univ Sci Technolog Med Sci. 2012-6
J Clin Invest. 2012-6-1